English

Edesa Biotech, Inc.

EDGAR

EDSA Current report (8-K) · filed 2026-10-23

157 filing records in this dataset, filed from 2012-04-16 to 2026-10-23. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2021 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-355 thousand USD

2021 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -13664932 USD Source
Operating Cash Flow: -13309611 USD Source

Cash and cash equivalents: 10.3 million USD 2026-06-30 Source
Exact value

10300000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 9.63 million shares 2026-06-30 Source
Exact value

9633223 shares

Reported share-count change

37.17% · 2.61 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

7022678 shares · 2025-06-30· Source
9633223 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2020-10-01 – 2021-09-30

Exact inputs and evidence

Revenue: 0 USD · 2020-10-01 – 2020-12-31 Source
Revenue: 0 USD · 2021-01-01 – 2021-03-31 Source
Revenue: 0 USD · 2021-04-01 – 2021-06-30 Source
Revenue: 0 USD · 2020-10-01 – 2021-09-30 Source
Revenue: 0 USD · 2020-10-01 – 2021-06-30 Source

Net income

-14.1 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -7200000 USD · 2024-10-01 – 2025-09-30 Source
Net income: -4957165 USD · 2024-10-01 – 2025-06-30 Source
Net income: -2247669 USD · 2025-10-01 – 2025-12-31 Source
Net income: -4218332 USD · 2026-01-01 – 2026-03-31 Source
Net income: -5407611 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-8.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -7300000 USD · 2024-10-01 – 2025-09-30 Source
Operating cash flow: -5601268 USD · 2024-10-01 – 2025-06-30 Source
Operating cash flow: -2100000 USD · 2025-10-01 – 2025-12-31 Source
Operating cash flow: -4100000 USD · 2025-10-01 – 2026-03-31 Source
Operating cash flow: -2100000 USD · 2025-10-01 – 2025-12-31 Source
Operating cash flow: -7200000 USD · 2025-10-01 – 2026-06-30 Source
Operating cash flow: -4100000 USD · 2025-10-01 – 2026-03-31 Source

Capital expenditure

0 USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Capital expenditure: 0 USD · 2022-10-01 – 2022-12-31 Source
Capital expenditure: 0 USD · 2022-10-01 – 2023-03-31 Source
Capital expenditure: 0 USD · 2022-10-01 – 2022-12-31 Source
Capital expenditure: 0 USD · 2022-10-01 – 2023-06-30 Source
Capital expenditure: 0 USD · 2022-10-01 – 2023-03-31 Source
Capital expenditure: 0 USD · 2022-10-01 – 2023-09-30 Source
Capital expenditure: 0 USD · 2022-10-01 – 2023-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-23.

Financial data available through: 2025-09-30.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2021-09-30
Operating income: 10 of 11 periods available· newest 2025-09-30
Net income: 10 of 11 periods available· newest 2025-09-30
Operating cash flow: 10 of 11 periods available· newest 2025-09-30
Capital expenditure: 8 of 11 periods available· newest 2023-09-30
Total assets: 10 of 11 periods available· newest 2025-09-30
Total liabilities: 6 of 11 periods available· newest 2024-09-30
Current assets: 10 of 11 periods available· newest 2025-09-30
Current liabilities: 10 of 11 periods available· newest 2025-09-30
Cash and cash equivalents: 10 of 11 periods available· newest 2025-09-30
long term debt: No compatible figures in this window
Shares outstanding: 10 of 11 periods available· newest 2025-09-30

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 1 million

Prior period

−USD 6.2 million

2023-10-01 – 2024-09-30
Current period

−USD 7.2 million

2024-10-01 – 2025-09-30

Exact inputs and evidence

-7200000 − -6200000 = -1000000 USD

-6200000 USD · 2023-10-01 – 2024-09-30
Inspect prior input Prior source
-7200000 USD · 2024-10-01 – 2025-09-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Edesa Biotech, Inc. · 2025-09-30 Edesa Biotech, Inc. (edgar:1540159) Year-over-year change in Net income: -1000000 USD Concept: fundies:NetIncome Period: 2024-10-01 to 2025-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -7200000 USD (2024-10-01 to 2025-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000117184325007914/edsa20250930_10k.htm#1442249 Filing: 000117184325007914 Input fundies:NetIncome: -6200000 USD (2023-10-01 to 2024-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000117184325007914/edsa20250930_10k.htm#1442451 Filing: 000117184325007914
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 2.4 million

Prior period

−USD 4.9 million

2023-10-01 – 2024-09-30
Current period

−USD 7.3 million

2024-10-01 – 2025-09-30

Exact inputs and evidence

-7300000 − -4900000 = -2400000 USD

-4900000 USD · 2023-10-01 – 2024-09-30
Inspect prior input Prior source
-7300000 USD · 2024-10-01 – 2025-09-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Edesa Biotech, Inc. · 2025-09-30 Edesa Biotech, Inc. (edgar:1540159) Year-over-year change in Operating cash flow: -2400000 USD Concept: fundies:OperatingCashFlow Period: 2024-10-01 to 2025-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -7300000 USD (2024-10-01 to 2025-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000117184325007914/edsa20250930_10k.htm#1441693 Filing: 000117184325007914 Input fundies:OperatingCashFlow: -4900000 USD (2023-10-01 to 2024-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000117184325007914/edsa20250930_10k.htm#1441924 Filing: 000117184325007914
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2020-10-01 – 2021-09-30

Revenue USD 0
Operating costs Derived USD 23.68 million
Operating income −USD 23.68 million
Tax, interest and other Derived −USD 10.34 million
Net income −USD 13.34 million

Cash

Operating cash flow −USD 13.66 million
Capital expenditure USD 6,146
Free cash flow Derived −USD 13.67 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2015 Operating loss: operating costs were 672% of revenue.
2016 Operating loss: operating costs were 486% of revenue.
2017 Operating loss: operating costs were 2,389% of revenue.
2018 Operating loss: operating costs were 2,497% of revenue.
2020 Operating loss: operating costs were 2,047% of revenue.
2021 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2015 2014-10-01 – 2015-09-30	758689	5097281 Derived	-4338592	-1495563 Derived	-2843029	-4686984 Derived	Source 2014-10-01 – 2015-09-30: 758689 USD Inspect Revenue Open source 2014-10-01 – 2015-09-30: -4338592 USD Inspect Operating Income Open source 2014-10-01 – 2015-09-30: -2843029 USD Inspect Net Income Open source 2014-10-01 – 2015-09-30: -4412395 USD Inspect Operating Cash Flow Open source 2014-10-01 – 2015-09-30: 274589 USD Inspect Capital Expenditure Open source
2016 2015-10-01 – 2016-09-30	1271689	6180045 Derived	-4908356	117724 Derived	-5026080	-4907900 Derived	Source 2015-10-01 – 2016-09-30: 1271689 USD Inspect Revenue Open source 2015-10-01 – 2016-09-30: -4908356 USD Inspect Operating Income Open source 2015-10-01 – 2016-09-30: -5026080 USD Inspect Net Income Open source 2015-10-01 – 2016-09-30: -4505629 USD Inspect Operating Cash Flow Open source 2015-10-01 – 2016-09-30: 402271 USD Inspect Capital Expenditure Open source
2017 2016-10-01 – 2017-09-30	228287	5452833 Derived	-5224546	-193898 Derived	-5030648	-5002382 Derived	Source 2016-10-01 – 2017-09-30: 228287 USD Inspect Revenue Open source 2016-10-01 – 2017-09-30: -5224546 USD Inspect Operating Income Open source 2016-10-01 – 2017-09-30: -5030648 USD Inspect Net Income Open source 2016-10-01 – 2017-09-30: -4699649 USD Inspect Operating Cash Flow Open source 2016-10-01 – 2017-09-30: 302733 USD Inspect Capital Expenditure Open source
2018 2017-10-01 – 2018-09-30	211849	5290099 Derived	-5078250	-39301 Derived	-5038949	-4998315 Derived	Source 2017-10-01 – 2018-09-30: 211849 USD Inspect Revenue Open source 2017-10-01 – 2018-09-30: -5078250 USD Inspect Operating Income Open source 2017-10-01 – 2018-09-30: -5038949 USD Inspect Net Income Open source 2017-10-01 – 2018-09-30: -4615505 USD Inspect Operating Cash Flow Open source 2017-10-01 – 2018-09-30: 382810 USD Inspect Capital Expenditure Open source
2020 2019-10-01 – 2020-09-30	328801	6729643 Derived	-6400842	-37412 Derived	-6363430	-4991196 Derived	Source 2019-10-01 – 2020-09-30: 328801 USD Inspect Revenue Open source 2019-10-01 – 2020-09-30: -6400842 USD Inspect Operating Income Open source 2019-10-01 – 2020-09-30: -6363430 USD Inspect Net Income Open source 2019-10-01 – 2020-09-30: -4986340 USD Inspect Operating Cash Flow Open source 2019-10-01 – 2020-09-30: 4856 USD Inspect Capital Expenditure Open source
2021 2020-10-01 – 2021-09-30	0	23681332 Derived	-23681332	-10338182 Derived	-13343150	-13671078 Derived	Source 2020-10-01 – 2021-09-30: 0 USD Inspect Revenue Open source 2020-10-01 – 2021-09-30: -23681332 USD Inspect Operating Income Open source 2020-10-01 – 2021-09-30: -13343150 USD Inspect Net Income Open source 2020-10-01 – 2021-09-30: -13664932 USD Inspect Operating Cash Flow Open source 2020-10-01 – 2021-09-30: 6146 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-09-30	Revenue	758689	Revenue: 758689 Open source
20162016-09-30	Revenue	1271689	Revenue: 1271689 Open source
20172017-09-30	Revenue	228287	Revenue: 228287 Open source
20182018-09-30	Revenue	211849	Revenue: 211849 Open source
20202020-09-30	Revenue	328801	Revenue: 328801 Open source
20212021-09-30	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-09-30	Year over year	No prior comparable period	Revenue: 758689 Open source
20162016-09-30	Year over year	67.6%	Revenue: 1271689 Open source Revenue: 758689 Open source
20172017-09-30	Year over year	-82%	Revenue: 228287 Open source Revenue: 1271689 Open source
20182018-09-30	Year over year	-7.2%	Revenue: 211849 Open source Revenue: 228287 Open source
20202020-09-30	Year over year	No prior comparable period	Revenue: 328801 Open source
20212021-09-30	Year over year	-100%	Revenue: 0 Open source Revenue: 328801 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,946.7% 2020

Net margin -1,935.3% 2020

Free cash flow margin -1,518% 2020

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20152015-09-30	Operating margin	-571.9%	Operating Income: -4338592 Open source Revenue: 758689 Open source
20162016-09-30	Operating margin	-386%	Operating Income: -4908356 Open source Revenue: 1271689 Open source
20172017-09-30	Operating margin	-2,288.6%	Operating Income: -5224546 Open source Revenue: 228287 Open source
20182018-09-30	Operating margin	-2,397.1%	Operating Income: -5078250 Open source Revenue: 211849 Open source
20202020-09-30	Operating margin	-1,946.7%	Operating Income: -6400842 Open source Revenue: 328801 Open source
20212021-09-30	Operating margin	Not reported	Operating Income: -23681332 Open source Revenue: 0 Open source
20152015-09-30	Net margin	-374.7%	Net Income: -2843029 Open source Revenue: 758689 Open source
20162016-09-30	Net margin	-395.2%	Net Income: -5026080 Open source Revenue: 1271689 Open source
20172017-09-30	Net margin	-2,203.7%	Net Income: -5030648 Open source Revenue: 228287 Open source
20182018-09-30	Net margin	-2,378.6%	Net Income: -5038949 Open source Revenue: 211849 Open source
20202020-09-30	Net margin	-1,935.3%	Net Income: -6363430 Open source Revenue: 328801 Open source
20212021-09-30	Net margin	Not reported	Net Income: -13343150 Open source Revenue: 0 Open source
20152015-09-30	Free cash flow margin	-617.8%	Revenue: 758689 Open source Operating Cash Flow: -4412395 Open source Capital Expenditure: 274589 Open source
20162016-09-30	Free cash flow margin	-385.9%	Revenue: 1271689 Open source Operating Cash Flow: -4505629 Open source Capital Expenditure: 402271 Open source
20172017-09-30	Free cash flow margin	-2,191.3%	Revenue: 228287 Open source Operating Cash Flow: -4699649 Open source Capital Expenditure: 302733 Open source
20182018-09-30	Free cash flow margin	-2,359.4%	Revenue: 211849 Open source Operating Cash Flow: -4615505 Open source Capital Expenditure: 382810 Open source
20202020-09-30	Free cash flow margin	-1,518%	Revenue: 328801 Open source Operating Cash Flow: -4986340 Open source Capital Expenditure: 4856 Open source
20212021-09-30	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -13664932 Open source Capital Expenditure: 6146 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -13.7M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-09-30	Operating cash flow	-4412395	Operating Cash Flow: -4412395 Open source
20162016-09-30	Operating cash flow	-4505629	Operating Cash Flow: -4505629 Open source
20172017-09-30	Operating cash flow	-4699649	Operating Cash Flow: -4699649 Open source
20182018-09-30	Operating cash flow	-4615505	Operating Cash Flow: -4615505 Open source
20202020-09-30	Operating cash flow	-4986340	Operating Cash Flow: -4986340 Open source
20212021-09-30	Operating cash flow	-13664932	Operating Cash Flow: -13664932 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -13.7M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-09-30	Free cash flow	-4686984	Operating Cash Flow: -4412395 Open source Capital Expenditure: 274589 Open source
20162016-09-30	Free cash flow	-4907900	Operating Cash Flow: -4505629 Open source Capital Expenditure: 402271 Open source
20172017-09-30	Free cash flow	-5002382	Operating Cash Flow: -4699649 Open source Capital Expenditure: 302733 Open source
20182018-09-30	Free cash flow	-4998315	Operating Cash Flow: -4615505 Open source Capital Expenditure: 382810 Open source
20202020-09-30	Free cash flow	-4991196	Operating Cash Flow: -4986340 Open source Capital Expenditure: 4856 Open source
20212021-09-30	Free cash flow	-13671078	Operating Cash Flow: -13664932 Open source Capital Expenditure: 6146 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

10.5% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20152015-09-30	Liabilities / assets	22.9%	Total Liabilities: 2380648 Open source Total Assets: 10385927 Open source
2016-09-30	Liabilities / assets	Not reported	Total Assets: 12937804 Open source
2017-09-30	Liabilities / assets	Not reported	Total Assets: 7720005 Open source
2018-09-30	Liabilities / assets	Not reported	Total Assets: 11779975 Open source
20202020-09-30	Liabilities / assets	15.4%	Total Liabilities: 1654245 Open source Total Assets: 10762375 Open source
20212021-09-30	Liabilities / assets	10.5%	Total Liabilities: 1526364 Open source Total Assets: 14584655 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

8.29× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20152015-09-30	Current assets / current liabilities	4.14×	Current Assets: 9866619 Open source Current Liabilities: 2380648 Open source
20162016-09-30	Current assets / current liabilities	19.4×	Current Assets: 12099655 Open source Current Liabilities: 623644 Open source
20172017-09-30	Current assets / current liabilities	21.06×	Current Assets: 6758447 Open source Current Liabilities: 320947 Open source
20182018-09-30	Current assets / current liabilities	21.6×	Current Assets: 10655984 Open source Current Liabilities: 493385 Open source
20202020-09-30	Current assets / current liabilities	5.3×	Current Assets: 8104018 Open source Current Liabilities: 1529857 Open source
20212021-09-30	Current assets / current liabilities	8.29×	Current Assets: 12090731 Open source Current Liabilities: 1458650 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2015 2014-10-01 – 2015-09-30	−USD 2.84 million Exact value Exact value: -2843029 USD 2014-10-01 – 2015-09-30: -2843029 USD Inspect Net Income Open source Share or cite Citation for Net Income · Edesa Biotech, Inc. · 2015-09-30 Edesa Biotech, Inc. (edgar:1540159) Net Income: -2843029 USD Concept: fundies:NetIncome Period: 2014-10-01 to 2015-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ANetIncome&period=2015-09-30&surface=latest&period_type=duration&start=2014-10-01&unit=USD&dimensions= Input fundies:NetIncome: -2843029 USD (2014-10-01 to 2015-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420417061791/sbot-20170930.xml#84481 Filing: 000114420417061791 The citation records this snapshot. The page link may show a newer release later.	−USD 4.41 million Exact value Exact value: -4412395 USD 2014-10-01 – 2015-09-30: -4412395 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Edesa Biotech, Inc. · 2015-09-30 Edesa Biotech, Inc. (edgar:1540159) Operating Cash Flow: -4412395 USD Concept: fundies:OperatingCashFlow Period: 2014-10-01 to 2015-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3AOperatingCashFlow&period=2015-09-30&surface=latest&period_type=duration&start=2014-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4412395 USD (2014-10-01 to 2015-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420417061791/sbot-20170930.xml#172165 Filing: 000114420417061791 The citation records this snapshot. The page link may show a newer release later.	USD 274,589 Exact value Exact value: 274589 USD 2014-10-01 – 2015-09-30: 274589 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Edesa Biotech, Inc. · 2015-09-30 Edesa Biotech, Inc. (edgar:1540159) Capital Expenditure: 274589 USD Concept: fundies:CapitalExpenditure Period: 2014-10-01 to 2015-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ACapitalExpenditure&period=2015-09-30&surface=latest&period_type=duration&start=2014-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 274589 USD (2014-10-01 to 2015-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420417061791/sbot-20170930.xml#172362 Filing: 000114420417061791 The citation records this snapshot. The page link may show a newer release later.	−USD 4.69 million Calculation and evidence -4412395 − 274589 USD Exact free cash flow: -4686984 USD 2014-10-01 – 2015-09-30: -4412395 USD · Inspect Operating Cash Flow · Source 2014-10-01 – 2015-09-30: 274589 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Edesa Biotech, Inc. · 2015-09-30 Edesa Biotech, Inc. (edgar:1540159) Free cash flow: -4686984 USD Concept: free-cash-flow Period: 2014-10-01 to 2015-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4412395 USD (2014-10-01 to 2015-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420417061791/sbot-20170930.xml#172165 Filing: 000114420417061791 Input fundies:CapitalExpenditure: 274589 USD (2014-10-01 to 2015-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420417061791/sbot-20170930.xml#172362 Filing: 000114420417061791 The citation records this snapshot. The page link may show a newer release later.
2016 2015-10-01 – 2016-09-30	−USD 5.03 million Exact value Exact value: -5026080 USD 2015-10-01 – 2016-09-30: -5026080 USD Inspect Net Income Open source Share or cite Citation for Net Income · Edesa Biotech, Inc. · 2016-09-30 Edesa Biotech, Inc. (edgar:1540159) Net Income: -5026080 USD Concept: fundies:NetIncome Period: 2015-10-01 to 2016-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ANetIncome&period=2016-09-30&surface=latest&period_type=duration&start=2015-10-01&unit=USD&dimensions= Input fundies:NetIncome: -5026080 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420417061791/sbot-20170930.xml#88910 Filing: 000114420417061791 The citation records this snapshot. The page link may show a newer release later.	−USD 4.51 million Exact value Exact value: -4505629 USD 2015-10-01 – 2016-09-30: -4505629 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Edesa Biotech, Inc. · 2016-09-30 Edesa Biotech, Inc. (edgar:1540159) Operating Cash Flow: -4505629 USD Concept: fundies:OperatingCashFlow Period: 2015-10-01 to 2016-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3AOperatingCashFlow&period=2016-09-30&surface=latest&period_type=duration&start=2015-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4505629 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420417061791/sbot-20170930.xml#92988 Filing: 000114420417061791 The citation records this snapshot. The page link may show a newer release later.	USD 402,271 Exact value Exact value: 402271 USD 2015-10-01 – 2016-09-30: 402271 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Edesa Biotech, Inc. · 2016-09-30 Edesa Biotech, Inc. (edgar:1540159) Capital Expenditure: 402271 USD Concept: fundies:CapitalExpenditure Period: 2015-10-01 to 2016-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ACapitalExpenditure&period=2016-09-30&surface=latest&period_type=duration&start=2015-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 402271 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420417061791/sbot-20170930.xml#93380 Filing: 000114420417061791 The citation records this snapshot. The page link may show a newer release later.	−USD 4.91 million Calculation and evidence -4505629 − 402271 USD Exact free cash flow: -4907900 USD 2015-10-01 – 2016-09-30: -4505629 USD · Inspect Operating Cash Flow · Source 2015-10-01 – 2016-09-30: 402271 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Edesa Biotech, Inc. · 2016-09-30 Edesa Biotech, Inc. (edgar:1540159) Free cash flow: -4907900 USD Concept: free-cash-flow Period: 2015-10-01 to 2016-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4505629 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420417061791/sbot-20170930.xml#92988 Filing: 000114420417061791 Input fundies:CapitalExpenditure: 402271 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420417061791/sbot-20170930.xml#93380 Filing: 000114420417061791 The citation records this snapshot. The page link may show a newer release later.
2017 2016-10-01 – 2017-09-30	−USD 5.03 million Exact value Exact value: -5030648 USD 2016-10-01 – 2017-09-30: -5030648 USD Inspect Net Income Open source Share or cite Citation for Net Income · Edesa Biotech, Inc. · 2017-09-30 Edesa Biotech, Inc. (edgar:1540159) Net Income: -5030648 USD Concept: fundies:NetIncome Period: 2016-10-01 to 2017-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ANetIncome&period=2017-09-30&surface=latest&period_type=duration&start=2016-10-01&unit=USD&dimensions= Input fundies:NetIncome: -5030648 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420418062614/sbot-20180930.xml#2007521 Filing: 000114420418062614 The citation records this snapshot. The page link may show a newer release later.	−USD 4.7 million Exact value Exact value: -4699649 USD 2016-10-01 – 2017-09-30: -4699649 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Edesa Biotech, Inc. · 2017-09-30 Edesa Biotech, Inc. (edgar:1540159) Operating Cash Flow: -4699649 USD Concept: fundies:OperatingCashFlow Period: 2016-10-01 to 2017-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3AOperatingCashFlow&period=2017-09-30&surface=latest&period_type=duration&start=2016-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4699649 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420418062614/sbot-20180930.xml#89773 Filing: 000114420418062614 The citation records this snapshot. The page link may show a newer release later.	USD 302,733 Exact value Exact value: 302733 USD 2016-10-01 – 2017-09-30: 302733 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Edesa Biotech, Inc. · 2017-09-30 Edesa Biotech, Inc. (edgar:1540159) Capital Expenditure: 302733 USD Concept: fundies:CapitalExpenditure Period: 2016-10-01 to 2017-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ACapitalExpenditure&period=2017-09-30&surface=latest&period_type=duration&start=2016-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 302733 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420418062614/sbot-20180930.xml#90167 Filing: 000114420418062614 The citation records this snapshot. The page link may show a newer release later.	−USD 5 million Calculation and evidence -4699649 − 302733 USD Exact free cash flow: -5002382 USD 2016-10-01 – 2017-09-30: -4699649 USD · Inspect Operating Cash Flow · Source 2016-10-01 – 2017-09-30: 302733 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Edesa Biotech, Inc. · 2017-09-30 Edesa Biotech, Inc. (edgar:1540159) Free cash flow: -5002382 USD Concept: free-cash-flow Period: 2016-10-01 to 2017-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4699649 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420418062614/sbot-20180930.xml#89773 Filing: 000114420418062614 Input fundies:CapitalExpenditure: 302733 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420418062614/sbot-20180930.xml#90167 Filing: 000114420418062614 The citation records this snapshot. The page link may show a newer release later.
2018 2017-10-01 – 2018-09-30	−USD 5.04 million Exact value Exact value: -5038949 USD 2017-10-01 – 2018-09-30: -5038949 USD Inspect Net Income Open source Share or cite Citation for Net Income · Edesa Biotech, Inc. · 2018-09-30 Edesa Biotech, Inc. (edgar:1540159) Net Income: -5038949 USD Concept: fundies:NetIncome Period: 2017-10-01 to 2018-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ANetIncome&period=2018-09-30&surface=latest&period_type=duration&start=2017-10-01&unit=USD&dimensions= Input fundies:NetIncome: -5038949 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420418062614/sbot-20180930.xml#2007381 Filing: 000114420418062614 The citation records this snapshot. The page link may show a newer release later.	−USD 4.62 million Exact value Exact value: -4615505 USD 2017-10-01 – 2018-09-30: -4615505 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Edesa Biotech, Inc. · 2018-09-30 Edesa Biotech, Inc. (edgar:1540159) Operating Cash Flow: -4615505 USD Concept: fundies:OperatingCashFlow Period: 2017-10-01 to 2018-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3AOperatingCashFlow&period=2018-09-30&surface=latest&period_type=duration&start=2017-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4615505 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420418062614/sbot-20180930.xml#89575 Filing: 000114420418062614 The citation records this snapshot. The page link may show a newer release later.	USD 382,810 Exact value Exact value: 382810 USD 2017-10-01 – 2018-09-30: 382810 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Edesa Biotech, Inc. · 2018-09-30 Edesa Biotech, Inc. (edgar:1540159) Capital Expenditure: 382810 USD Concept: fundies:CapitalExpenditure Period: 2017-10-01 to 2018-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ACapitalExpenditure&period=2018-09-30&surface=latest&period_type=duration&start=2017-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 382810 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420418062614/sbot-20180930.xml#89971 Filing: 000114420418062614 The citation records this snapshot. The page link may show a newer release later.	−USD 5 million Calculation and evidence -4615505 − 382810 USD Exact free cash flow: -4998315 USD 2017-10-01 – 2018-09-30: -4615505 USD · Inspect Operating Cash Flow · Source 2017-10-01 – 2018-09-30: 382810 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Edesa Biotech, Inc. · 2018-09-30 Edesa Biotech, Inc. (edgar:1540159) Free cash flow: -4998315 USD Concept: free-cash-flow Period: 2017-10-01 to 2018-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4615505 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420418062614/sbot-20180930.xml#89575 Filing: 000114420418062614 Input fundies:CapitalExpenditure: 382810 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000114420418062614/sbot-20180930.xml#89971 Filing: 000114420418062614 The citation records this snapshot. The page link may show a newer release later.
2020 2019-10-01 – 2020-09-30	−USD 6.36 million Exact value Exact value: -6363430 USD 2019-10-01 – 2020-09-30: -6363430 USD Inspect Net Income Open source Share or cite Citation for Net Income · Edesa Biotech, Inc. · 2020-09-30 Edesa Biotech, Inc. (edgar:1540159) Net Income: -6363430 USD Concept: fundies:NetIncome Period: 2019-10-01 to 2020-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ANetIncome&period=2020-09-30&surface=latest&period_type=duration&start=2019-10-01&unit=USD&dimensions= Input fundies:NetIncome: -6363430 USD (2019-10-01 to 2020-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495421013551/edsa_10k.htm#2807 Filing: 000165495421013551 The citation records this snapshot. The page link may show a newer release later.	−USD 4.99 million Exact value Exact value: -4986340 USD 2019-10-01 – 2020-09-30: -4986340 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Edesa Biotech, Inc. · 2020-09-30 Edesa Biotech, Inc. (edgar:1540159) Operating Cash Flow: -4986340 USD Concept: fundies:OperatingCashFlow Period: 2019-10-01 to 2020-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3AOperatingCashFlow&period=2020-09-30&surface=latest&period_type=duration&start=2019-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4986340 USD (2019-10-01 to 2020-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495421013551/edsa_10k.htm#884356 Filing: 000165495421013551 The citation records this snapshot. The page link may show a newer release later.	USD 4,856 Exact value Exact value: 4856 USD 2019-10-01 – 2020-09-30: 4856 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Edesa Biotech, Inc. · 2020-09-30 Edesa Biotech, Inc. (edgar:1540159) Capital Expenditure: 4856 USD Concept: fundies:CapitalExpenditure Period: 2019-10-01 to 2020-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ACapitalExpenditure&period=2020-09-30&surface=latest&period_type=duration&start=2019-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4856 USD (2019-10-01 to 2020-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495421013551/edsa_10k.htm#889639 Filing: 000165495421013551 The citation records this snapshot. The page link may show a newer release later.	−USD 4.99 million Calculation and evidence -4986340 − 4856 USD Exact free cash flow: -4991196 USD 2019-10-01 – 2020-09-30: -4986340 USD · Inspect Operating Cash Flow · Source 2019-10-01 – 2020-09-30: 4856 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Edesa Biotech, Inc. · 2020-09-30 Edesa Biotech, Inc. (edgar:1540159) Free cash flow: -4991196 USD Concept: free-cash-flow Period: 2019-10-01 to 2020-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4986340 USD (2019-10-01 to 2020-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495421013551/edsa_10k.htm#884356 Filing: 000165495421013551 Input fundies:CapitalExpenditure: 4856 USD (2019-10-01 to 2020-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495421013551/edsa_10k.htm#889639 Filing: 000165495421013551 The citation records this snapshot. The page link may show a newer release later.
2021 2020-10-01 – 2021-09-30	−USD 13.34 million Exact value Exact value: -13343150 USD 2020-10-01 – 2021-09-30: -13343150 USD Inspect Net Income Open source Share or cite Citation for Net Income · Edesa Biotech, Inc. · 2021-09-30 Edesa Biotech, Inc. (edgar:1540159) Net Income: -13343150 USD Concept: fundies:NetIncome Period: 2020-10-01 to 2021-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ANetIncome&period=2021-09-30&surface=latest&period_type=duration&start=2020-10-01&unit=USD&dimensions= Input fundies:NetIncome: -13343150 USD (2020-10-01 to 2021-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_10k.htm#819183 Filing: 000165495422016633 The citation records this snapshot. The page link may show a newer release later.	−USD 13.66 million Exact value Exact value: -13664932 USD 2020-10-01 – 2021-09-30: -13664932 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Edesa Biotech, Inc. · 2021-09-30 Edesa Biotech, Inc. (edgar:1540159) Operating Cash Flow: -13664932 USD Concept: fundies:OperatingCashFlow Period: 2020-10-01 to 2021-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3AOperatingCashFlow&period=2021-09-30&surface=latest&period_type=duration&start=2020-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13664932 USD (2020-10-01 to 2021-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_10k.htm#848525 Filing: 000165495422016633 The citation records this snapshot. The page link may show a newer release later.	USD 6,146 Exact value Exact value: 6146 USD 2020-10-01 – 2021-09-30: 6146 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Edesa Biotech, Inc. · 2021-09-30 Edesa Biotech, Inc. (edgar:1540159) Capital Expenditure: 6146 USD Concept: fundies:CapitalExpenditure Period: 2020-10-01 to 2021-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ACapitalExpenditure&period=2021-09-30&surface=latest&period_type=duration&start=2020-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6146 USD (2020-10-01 to 2021-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_10k.htm#852430 Filing: 000165495422016633 The citation records this snapshot. The page link may show a newer release later.	−USD 13.67 million Calculation and evidence -13664932 − 6146 USD Exact free cash flow: -13671078 USD 2020-10-01 – 2021-09-30: -13664932 USD · Inspect Operating Cash Flow · Source 2020-10-01 – 2021-09-30: 6146 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Edesa Biotech, Inc. · 2021-09-30 Edesa Biotech, Inc. (edgar:1540159) Free cash flow: -13671078 USD Concept: free-cash-flow Period: 2020-10-01 to 2021-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13664932 USD (2020-10-01 to 2021-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_10k.htm#848525 Filing: 000165495422016633 Input fundies:CapitalExpenditure: 6146 USD (2020-10-01 to 2021-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_10k.htm#852430 Filing: 000165495422016633 The citation records this snapshot. The page link may show a newer release later.
2022 2021-10-01 – 2022-09-30	−USD 17.55 million Exact value Exact value: -17548924 USD 2021-10-01 – 2022-09-30: -17548924 USD Inspect Net Income Open source Share or cite Citation for Net Income · Edesa Biotech, Inc. · 2022-09-30 Edesa Biotech, Inc. (edgar:1540159) Net Income: -17548924 USD Concept: fundies:NetIncome Period: 2021-10-01 to 2022-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ANetIncome&period=2022-09-30&surface=latest&period_type=duration&start=2021-10-01&unit=USD&dimensions= Input fundies:NetIncome: -17548924 USD (2021-10-01 to 2022-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_10k.htm#990503 Filing: 000165495423015632 The citation records this snapshot. The page link may show a newer release later.	−USD 12.28 million Exact value Exact value: -12279302 USD 2021-10-01 – 2022-09-30: -12279302 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Edesa Biotech, Inc. · 2022-09-30 Edesa Biotech, Inc. (edgar:1540159) Operating Cash Flow: -12279302 USD Concept: fundies:OperatingCashFlow Period: 2021-10-01 to 2022-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3AOperatingCashFlow&period=2022-09-30&surface=latest&period_type=duration&start=2021-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12279302 USD (2021-10-01 to 2022-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_10k.htm#1020479 Filing: 000165495423015632 The citation records this snapshot. The page link may show a newer release later.	USD 5,656 Exact value Exact value: 5656 USD 2021-10-01 – 2022-09-30: 5656 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Edesa Biotech, Inc. · 2022-09-30 Edesa Biotech, Inc. (edgar:1540159) Capital Expenditure: 5656 USD Concept: fundies:CapitalExpenditure Period: 2021-10-01 to 2022-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ACapitalExpenditure&period=2022-09-30&surface=latest&period_type=duration&start=2021-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5656 USD (2021-10-01 to 2022-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_10k.htm#1024409 Filing: 000165495423015632 The citation records this snapshot. The page link may show a newer release later.	−USD 12.28 million Calculation and evidence -12279302 − 5656 USD Exact free cash flow: -12284958 USD 2021-10-01 – 2022-09-30: -12279302 USD · Inspect Operating Cash Flow · Source 2021-10-01 – 2022-09-30: 5656 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Edesa Biotech, Inc. · 2022-09-30 Edesa Biotech, Inc. (edgar:1540159) Free cash flow: -12284958 USD Concept: free-cash-flow Period: 2021-10-01 to 2022-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12279302 USD (2021-10-01 to 2022-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_10k.htm#1020479 Filing: 000165495423015632 Input fundies:CapitalExpenditure: 5656 USD (2021-10-01 to 2022-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_10k.htm#1024409 Filing: 000165495423015632 The citation records this snapshot. The page link may show a newer release later.
2023 2022-10-01 – 2023-09-30	−USD 8.4 million Exact value Exact value: -8400000 USD 2022-10-01 – 2023-09-30: -8400000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Edesa Biotech, Inc. · 2023-09-30 Edesa Biotech, Inc. (edgar:1540159) Net Income: -8400000 USD Concept: fundies:NetIncome Period: 2022-10-01 to 2023-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ANetIncome&period=2023-09-30&surface=latest&period_type=duration&start=2022-10-01&unit=USD&dimensions= Input fundies:NetIncome: -8400000 USD (2022-10-01 to 2023-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000117184324006946/edsa20240930_10k.htm#1316414 Filing: 000117184324006946 The citation records this snapshot. The page link may show a newer release later.	−USD 6.6 million Exact value Exact value: -6600000 USD 2022-10-01 – 2023-09-30: -6600000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Edesa Biotech, Inc. · 2023-09-30 Edesa Biotech, Inc. (edgar:1540159) Operating Cash Flow: -6600000 USD Concept: fundies:OperatingCashFlow Period: 2022-10-01 to 2023-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3AOperatingCashFlow&period=2023-09-30&surface=latest&period_type=duration&start=2022-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6600000 USD (2022-10-01 to 2023-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000117184324006946/edsa20240930_10k.htm#1315882 Filing: 000117184324006946 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2022-10-01 – 2023-09-30: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Edesa Biotech, Inc. · 2023-09-30 Edesa Biotech, Inc. (edgar:1540159) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2022-10-01 to 2023-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ACapitalExpenditure&period=2023-09-30&surface=latest&period_type=duration&start=2022-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2022-10-01 to 2023-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_10k.htm#1023688 Filing: 000165495423015632 The citation records this snapshot. The page link may show a newer release later.	−USD 6.6 million Calculation and evidence -6600000 − 0 USD Exact free cash flow: -6600000 USD 2022-10-01 – 2023-09-30: -6600000 USD · Inspect Operating Cash Flow · Source 2022-10-01 – 2023-09-30: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Edesa Biotech, Inc. · 2023-09-30 Edesa Biotech, Inc. (edgar:1540159) Free cash flow: -6600000 USD Concept: free-cash-flow Period: 2022-10-01 to 2023-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6600000 USD (2022-10-01 to 2023-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000117184324006946/edsa20240930_10k.htm#1315882 Filing: 000117184324006946 Input fundies:CapitalExpenditure: 0 USD (2022-10-01 to 2023-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_10k.htm#1023688 Filing: 000165495423015632 The citation records this snapshot. The page link may show a newer release later.
2024 2023-10-01 – 2024-09-30	−USD 6.2 million Exact value Exact value: -6200000 USD 2023-10-01 – 2024-09-30: -6200000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Edesa Biotech, Inc. · 2024-09-30 Edesa Biotech, Inc. (edgar:1540159) Net Income: -6200000 USD Concept: fundies:NetIncome Period: 2023-10-01 to 2024-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ANetIncome&period=2024-09-30&surface=latest&period_type=duration&start=2023-10-01&unit=USD&dimensions= Input fundies:NetIncome: -6200000 USD (2023-10-01 to 2024-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000117184325007914/edsa20250930_10k.htm#1442451 Filing: 000117184325007914 The citation records this snapshot. The page link may show a newer release later.	−USD 4.9 million Exact value Exact value: -4900000 USD 2023-10-01 – 2024-09-30: -4900000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Edesa Biotech, Inc. · 2024-09-30 Edesa Biotech, Inc. (edgar:1540159) Operating Cash Flow: -4900000 USD Concept: fundies:OperatingCashFlow Period: 2023-10-01 to 2024-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3AOperatingCashFlow&period=2024-09-30&surface=latest&period_type=duration&start=2023-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4900000 USD (2023-10-01 to 2024-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000117184325007914/edsa20250930_10k.htm#1441924 Filing: 000117184325007914 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2024-10-01 – 2025-09-30	−USD 7.2 million Exact value Exact value: -7200000 USD 2024-10-01 – 2025-09-30: -7200000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Edesa Biotech, Inc. · 2025-09-30 Edesa Biotech, Inc. (edgar:1540159) Net Income: -7200000 USD Concept: fundies:NetIncome Period: 2024-10-01 to 2025-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3ANetIncome&period=2025-09-30&surface=latest&period_type=duration&start=2024-10-01&unit=USD&dimensions= Input fundies:NetIncome: -7200000 USD (2024-10-01 to 2025-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000117184325007914/edsa20250930_10k.htm#1442249 Filing: 000117184325007914 The citation records this snapshot. The page link may show a newer release later.	−USD 7.3 million Exact value Exact value: -7300000 USD 2024-10-01 – 2025-09-30: -7300000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Edesa Biotech, Inc. · 2025-09-30 Edesa Biotech, Inc. (edgar:1540159) Operating Cash Flow: -7300000 USD Concept: fundies:OperatingCashFlow Period: 2024-10-01 to 2025-09-30 Values: Latest reported Published: 2026-11-02T13:33:50Z Snapshot: be9d5a071fc6e85a8a475c8c101e6d8568964c73b186848183cada56a0f91cb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1540159/explain?concept=fundies%3AOperatingCashFlow&period=2025-09-30&surface=latest&period_type=duration&start=2024-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7300000 USD (2024-10-01 to 2025-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1540159/000117184325007914/edsa20250930_10k.htm#1441693 Filing: 000117184325007914 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

157 filings · 3,027 latest values · 3,051 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001540159, 1540159, EDSA, SBOT, SBOTF, edgar:1540159

Also known as EDESA BIOTECH, INC., EDESA BIOTECH, INC, EDESA BIOTECH, INC., Edesa Biotech, Inc., Stellar Biotechnologies, Inc., Stellar Biotechnologies, Inc.

Edesa Biotech, Inc.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Net income

Operating cash flow

Where revenue goes

2021 2020-10-01 – 2021-09-30

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation